Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 701–800 of 1,035
Hypoxic tumor microenvironment: Implications for cancer therapy
Roy, S., Kumaravel, S., Sharma, A., Duran, C. L., Bayless, K. J., & Chakraborty, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220934038 · Cited by 141
Understanding tumor endothelial cell abnormalities to develop ideal anti‐angiogenic therapies
Hida, K., Hida, Y., & Shindoh, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00704.x · Cited by 138
Flow‐compensated intravoxel incoherent motion diffusion imaging
Wetscherek, A., Stieltjes, B., & Laun, F. B. (2014) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25410 · Cited by 132
Two-Photon Absorbing Nanocrystal Sensors for Ratiometric Detection of Oxygen
McLaurin, E. J., Greytak, A. B., Bawendi, M. G., & Nocera, D. G. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902712b · Cited by 125
Cerniglia, G. J., Pore, N., Tsai, J. H., Schultz, S., Mick, R., Choe, R., Xing, X., Durduran, T., Yodh, A. G., Evans, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006539 · Cited by 125
“More recently Jain and colleagues showed that PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6539 anti-angiogenic therapy can result in a ‘‘normalization’’ of aberrant tumor vasculature in such as way as to improve oxygenation and blood flow that could enhance the efficacy of subsequent radiation and…”
BackgroundMethodInfluentialGlycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis
Chandler, K. B., Costello, C. E., & Rahimi, N. (2019) · Cells · doi:10.3390/cells8060544 · Cited by 136
Vascular Microenvironment, Tumor Immunity and Immunotherapy
Lamplugh, Z. L., & Fan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.811485 · Cited by 140
Davis, G. E., Koh, W., & Stratman, A. N. (2007) · Birth Defects Research Part C: Embryo Today: Reviews · doi:10.1002/bdrc.20107 · Cited by 125
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
Weiss, A., Ding, X., B, J. R. V. B., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M. G., Shen, L., Schlingemann, R. O., et al. (2015) · Angiogenesis · doi:10.1007/s10456-015-9462-9 · Cited by 124
“The capacity to normalize the tumor vasculature provides angiostatic strategies with outstanding combination therapy features [56, 57].”
BackgroundTumor angiogenesis and novel antiangiogenic strategies
Gordon, M. S., Mendelson, D. S., & Kato, G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25026 · Cited by 136
“depicting the concomitant changes in pericyte (red) and basement membrane (blue) coverage.(7) Reprinted with permission from AAAS.”
BackgroundInfluentialIFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor
Gerber, S. A., Sedlacek, A. L., Cron, K. R., Murphy, S. P., Frelinger, J. G., & Lord, E. M. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.02.041 · Cited by 124
“Additionally, our previous work has demonstrated that IFN-g up-regulates the adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) on tumor endothelium(10) and promotes vessel normalization,(22) consequences that may promote antitumor activity by facilitating immune cell infiltration.(32,33) Similarly, Lu et al…”
Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Cornelissen, B. T., & Vallis, K. A. (2010) · Current Drug Discovery Technologies · doi:10.2174/157016310793360657 · Cited by 138
“Vascular normalisation techniques could be applied ahead of radiopharmaceutical administration, thereby reducing the poorly vascularised areas in the tumour tissue for a short period of time, and increasing radiopharmaceutical delivery during that time [183].”
Komatsu, M., & Ruoslahti, E. I. (2005) · Nature Medicine · doi:10.1038/nm1324 · Cited by 140
Lammers, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.028 · Cited by 135
“hints towards an enhanced ‘vessel normalization’ [197,198] in tumors”
BackgroundSun, D., Liu, Y., Yu, Q., Zhou, Y., Zhang, R., Chen, X., Hong, A., & Liu, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.031 · Cited by 125
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Arjaans, M., Oude Munnink, T. H., Oosting, S. F., Terwisscha van Scheltinga, A. G. T., Gietema, J. A., Garbacik, E. T., Timmer-Bosscha, H., Lub-de Hooge, M. N., Schröder, C. P., & de Vries, E. G. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3518 · Cited by 121
Wang, R., Qiu, M., Zhang, L., Sui, M., Xiao, L., Yu, Q., Ye, C., Chen, S., & Zhou, X. H. (2023) · Advanced Materials · doi:10.1002/adma.202306748 · Cited by 129
Quantitative multimodality imaging in cancer research and therapy
Yankeelov, T. E., Abramson, R. G., & Quarles, C. C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.134 · Cited by 123
Yang, X., & Knopp, M. V. (2011) · BioMed Research International · doi:10.1155/2011/732848 · Cited by 123
“In fact, daily or weekly repeats of DCE-MRI examinations are common in preclinical and clinical studies, allowing researchers to capture rapid change in tumor vasculature during the short “normalization window” after administration of an antiangiogenic agent [7].”
BackgroundRemodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy
Gkretsi, V., Stylianou, A., Papageorgis, P., Polydorou, C., & Stylianopoulos, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00214 · Cited by 123
“Anti-angiogenic treatment worked well in many preclinical models but failed to improve overall survival when used as monotherapy in most cases in the clinic (88).”
BackgroundInhibiting cancer cell hallmark features through nuclear export inhibition
Sun, Q., Chen, X., Zhou, Q., Burstein, E., Yang, S., & Jia, D. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.10 · Cited by 140
Angiogenesis and antiangiogenic therapy in endometriosis
Becker, C. M., & D’Amato, R. J. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.04.008 · Cited by 131
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer
Krämer, I., & Lipp, H. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00800.x · Cited by 126
“Preclinical studies have also demonstrated that other effects of VEGF inhibition may include regression of the immature blood vessels characteristic of tumours (32), reversal of the structural and functional abnormalities in the surviving tumour vasculature (‘normalization’) (18, 33), and inhibition of the development…”
BackgroundVEGFR and Type-V RTK Activation and Signaling
Shibuya, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009092 · Cited by 120
“Vascular normalization may decrease the abnormal vascular permeability of tumor vessels, resulting in normalized intratumoral pressure and better distribution of anticancer chemicals (Jain 2005).”
BackgroundACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI
Gerstner, E. R., Zhang, Z., Fink, J. R., Muzi, M., Hanna, L., Greco, E., Prah, M., Schmainda, K. M., Mintz, A., Kostakoglu, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2529 · Cited by 122
“This abnormal vasculature is inefficient and heterogeneous resulting in overall poor delivery of oxygen leading to hypoxia and poor delivery of nutrients or cytotoxic chemotherapy to tumor tissue (4).”
BackgroundSUSHI: Sparsity-Based Ultrasound Super-Resolution Hemodynamic Imaging
Bar‐Zion, A., Solomon, O., Tremblay‐Darveau, C., Adam, D., & Eldar, Y. C. (2018) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2018.2873380 · Cited by 128
“microvascular level [5], resolving these vessels could enable fast and direct treatment monitoring capability, valuable for both research and clinical applications.”
BackgroundSalvage therapy with single agent bevacizumab for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9957-6 · Cited by 130
Gao, W., Sweeney, C., Walsh, C., Rooney, P., McCormick, J., Veale, D. J., & Fearon, U. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201978 · Cited by 120
“Beneficial effects of Notch signalling blockade include inducing tumour cell apoptosis, suppressing neuroblastoma cell growth and differentiation, In contrast, this therapeutic approach may conversely accelerate tumour metastasis and invasion,(83) 84 suggesting that vessel stabilisation, normalisation and improvement…”
Wong, H. K., Lahdenranta, J., Kamoun, W. S., Chan, A. W., McClatchey, A. I., Plotkin, S. R., Jain, R. K., & di Tomaso, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3107 · Cited by 129
“This is very different from the “classic” normalization seen in brain tumors treated with anti-VEGF therapies (34).”
BackgroundSelf-citationPonte, J. F., Ab, O., Lanieri, L., Lee, J., Coccia, J. A., Bartle, L. M., Themeles, M., Zhou, Y., Pinkas, J., & Ruiz‐Soto, R. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.002 · Cited by 127
“In this regard, it is well established that bevacizumab treatment can induce normalization of the tumor vasculature, an effect that has been suggested to result in reduced interstitial pressures and improved drug delivery [57].”
Molecular mechanisms underlying therapeutic potential of pericytes
Harrell, C. R., Marković, B. S., Fellabaum, C., Arsenijević, A., Djonov, V., & Volarević, V. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0423-7 · Cited by 135
“drug, and nutrient delivery to the tumor [91].”
BackgroundUltrasound and microbubbles to beat barriers in tumors: Improving delivery of nanomedicine
Snipstad, S., Vikedal, K., Maardalen, M., Kurbatskaya, A., Sulheim, E., & Davies, C. D. L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113847 · Cited by 127
Inflammatory angiogenesis in atherogenesis—a double-edged sword
Ribatti, D., Levi‐Schaffer, F., & Kovanen, P. T. (2008) · Annals of Medicine · doi:10.1080/07853890802186913 · Cited by 139
“Thus, less leaky vasculature, characterized by a more restrictive basement membrane surrounded by pericytes (163), might support a more favorable microenvironment promoting plaque stabilization (164).”
BackgroundKano, M. R., Komuta, Y., Iwata, C., Oka, M., Shirai, Y., Morishita, Y., Ouchi, Y., Kataoka, K., & Miyazono, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01003.x · Cited by 121
Zhao, C., Wang, X., Zhao, Y., Li, Z., Lin, S., Wei, Y., & Yang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021768 · Cited by 130
“Vasculatures in tumors often are architecturally different from their normal counterparts — they are haphazardly constructed, irregularly shaped and tortuous [6–8].”
BackgroundAngiogenesis as a Therapeutic Target in Malignant Gliomas
Chi, A. S., Sorensen, A. G., Jain, R. K., & Batchelor, T. T. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0272 · Cited by 128
“One hypothesis is that bevacizumab may principally be serving to transiently “normalize” tumor vasculature and improve chemotherapy delivery and efficacy [82], whereas the observed clinical efficacy of broad-spectrum TKIs as single agents may result from their ability to inhibit multiple pathogenic signaling pathways…”
BackgroundSelf-citationWang, Y., Chen, H., Liu, Y., Wu, J., Zhou, P., Wang, Y., Li, R., Yang, X., & Zhang, N. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.081 · Cited by 120
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
Miao, L., Wang, Y., Lin, C. M., Xiong, Y., Chen, N., Zhang, L., Kim, W. Y., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.027 · Cited by 118
Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis
Seano, G., Chiaverina, G., Gagliardi, P. A., di Blasio, L., Puliafito, A., Bouvard, C., Sessa, R., Tarone, G., Sorokin, L., Helley, D., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3036 · Cited by 119
Self-citationHosaka, K., Yang, Y., Seki, T., Nakamura, M., Andersson, P., Rouhi, P., Yang, X., Jensen, L. D., Lim, S., Feng, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3129 · Cited by 124
Chakroborty, D., Sarkar, C., Yu, H., Wang, J., Liu, Z., Dasgupta, P. S., & Basu, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108696108 · Cited by 119
“Therefore, in the treatment of cancer patients, normalization of tumor blood vessels may be an important approach to increase the efficacy of anticancer drugs (1, 3, 7).”
BackgroundControlled Delivery of Nitric Oxide for Cancer Therapy
Alimoradi, H., Greish, K. F., Gamble, A. B., & Giles, G. I. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190429111306 · Cited by 126
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 129
Vascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021) · Cancers · doi:10.3390/cancers13174444 · Cited by 134
Integrins: Signaling, disease, and therapy
Huveneers, S., Truong, H. H., & Danen, E. H. J. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701481808 · Cited by 132
Langenkamp, E., & Molema, G. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0642-4 · Cited by 119
“…biological consequence of treatment with these inhibitors is unknown, but anti-angiogenic therapeutic strategies have been documented to result in hypoxia (Casanovas et al. 2005; Shaked et al. 2006), endothelial cell apoptosis (Laird et al. 2002), and normalization of the vasculature (Jain 2005).”
BackgroundSmits, M., Mir, S. E., Nilsson, R. J. A., van der Stoop, P. M., Niers, J. M., Marquez, V. E., Cloos, J., Breakefield, X. O., Krichevsky, A. M., Noske, D. P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016282 · Cited by 118
Yi, Y., Yu, M., Feng, C., Hao, H., Zeng, W., Lin, C., Chen, H., Lv, F., Zhu, D., Ji, X., et al. (2022) · Matter · doi:10.1016/j.matt.2022.04.032 · Cited by 120
Goel, S., Gupta, N., Walcott, B. P., Snuderl, M., Kesler, C. T., Kirkpatrick, N. D., Heishi, T., Huang, Y., Martin, J. D., Ager, E., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt164 · Cited by 117
“The accompanying increase in tumor perfusion and reduction in hypoxia are clinically relevant: reduced tumor perfusion and tumor hypoxia are known determinants of aggressive tumor behavior, insensitivity to chemo- and radiotherapy, and a poor prognosis (9,36,37).”
BackgroundSelf-citationLequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117
Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.010 · Cited by 119
Self-citationHypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Jain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K., & Virmani, R. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0979 · Cited by 117
“From Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.”
BackgroundSelf-citationTokarz, P., & Błasiak, J. (2012) · Acta Biochimica Polonica · doi:10.18388/abp.2012_2079 · Cited by 123
“Angiogenesis is regulated by pro- and anti-angiogenic factors (Jain, 2005).”
Heterogeneity of tumor endothelial cells and drug delivery
Hida, K., Maishi, N., Sakurai, Y., Hida, Y., & Harashima, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.008 · Cited by 122
Huo, M., Wang, H., Zhang, Y., Cai, H., Zhang, P., Li, L., Zhou, J., & Yin, T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.017 · Cited by 123
Davis, G. E., & Saunders, W. B. (2006) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650008 · Cited by 129
The Met pathway: master switch and drug target in cancer progression
Mazzone, M., & Comoglio, P. M. (2006) · The FASEB Journal · doi:10.1096/fj.06-5947rev · Cited by 124
“One of the most important environmental elements within the tumor mass is represented by blood vessels (83).”
BackgroundPlasma jet-induced tissue oxygenation: potentialities for new therapeutic strategies
Collet, G., Robert, É., Lenoir, A., Vandamme, M., Darny, T., Dozias, S., Kiéda, C., & Pouvesle, J. (2014) · Plasma Sources Science and Technology · doi:10.1088/0963-0252/23/1/012005 · Cited by 127
“Consequently, a new axis of research is devoted to blood vessel normalization aiming to recover a functional vasculature from non-functional tumor vessels [13, 14].”
BackgroundReynolds, A. R. (2010) · Dose-Response · doi:10.2203/dose-response.09-049.reynolds · Cited by 132
Patella, F., Schug, Z. T., Persi, E., Neilson, L. J., Erami, Z., Avanzato, D., Maione, F., Hernandez-Fernaud, J. R., Mackay, G., Zheng, L., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.045575 · Cited by 115
“Different drugs were injected intradermally with the following amounts: (1) 100 ng, 500 ng, 1 g, and 2 g of etomoxir; (2) 1 g, 2 g, 5 g, and 10 g of oxfenicine; (3) 100 ng etomoxir combined with 500 ng pyruvate and 5 g dichloroacetate; (4) gadolinium 100 M was co-injected with 500 ng of etomoxir; and (5) saline soluti…”
BackgroundMethodInfluentialTargeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines
Omidi, Y., & Barar, J. (2014) · PubMed · doi:10.5681/bi.2014.021 · Cited by 99
Cun, X., Ruan, S., Chen, J., Zhang, L., Li, J., He, Q., & Gao, H. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.12.002 · Cited by 117
Tamura, R., Tanaka, T., Miyake, K., Yoshida, K., & Sasaki, H. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0284-x · Cited by 125
“In contrast, Bev does not inhibit other angiogenic processes (intussusception, co-option, and vascular mimicry) [27, 28].”
BackgroundTargeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 124
“This leads to a reduction of tumor interstitial pressure, improved drug delivery, and the realization of the “oxygen effect” during radiotherapy [299,300].”
BackgroundTargeting Angiogenesis-Dependent Calcified Neoplasms Using Combined Polymer Therapeutics
Segal, E., Pan, H., Ofek, P., Udagawa, T., Kopečková, P., Kopec̆ek, J., & Satchi‐Fainaro, R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005233 · Cited by 116
“Some antiangiogenic agents can ‘‘normalize’’ the abnormal tumor vasculature, resulting in more efficient delivery of drugs and oxygen to the targeted cancer cells, and enhancement of the efficacy of radiation therapy and chemotherapeutic agents [68].”
BackgroundGenetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis
Fuster, M. M., Wang, L., Castagnola, J., Sikora, L., Reddi, K., Lee, P. H. A., Radek, K. A., Schuksz, M., Bishop, J. R., Gallo, R. L., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200610086 · Cited by 116
“As observed in other tumor models, the microvasculature in LLC tumors displayed a highly chaotic morphology compared with normal vasculature (Carmeliet and Jain, 2000; Jain, 2005).”
BackgroundThe Relationship between Tumor Blood Flow, Angiogenesis, Tumor Hypoxia, and Aerobic Glycolysis
Østergaard, L., Tietze, A., Nielsen, T., Drasbek, K. R., Mouridsen, K., Jespersen, S. N., & Horsman, M. R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0964 · Cited by 113
“These findings have led to the hypothesis that antiangiogenic drugs prune the chaotic tumor microvasculature to provide a more even distribution of blood and anticancer drugs across tumors, thereby improving tissue oxygenation and drug responses (9).”
BackgroundSandri, C., Caccavari, F., Valdembri, D., Camillo, C., Veltel, S., Santambrogio, M., Lanzetti, L., Bussolino, F., Ivaska, J., & Serini, G. (2012) · Cell Research · doi:10.1038/cr.2012.110 · Cited by 129
A preclinical and clinical review of aflibercept for the management of cancer
Gaya, A. M., & Tse, V. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.008 · Cited by 123
Combinatorial therapy in tumor microenvironment: Where do we stand?
Kumari, S., Advani, D., Sharma, S., Ambasta, R. K., & Kumar, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188585 · Cited by 128
The Role of Angiopoietins During Angiogenesis in Gliomas
Reiss, Y., Machein, M. R., & Plate, K. H. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00116.x · Cited by 115
“In a syngeneic rat glioma model we demonstrated that in the presence of Ang-1, tumors induce a more functional, “normalized” vascular network, which led to better tumor perfusion and growth (24, 30).”
BackgroundInitial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
Maris, J. M., Courtright, J., Houghton, P. J., Morton, C. L., Gorlick, R. G., Kolb, E. A., Lock, R. B., Tajbakhsh, M., Reynolds, C. P., Keir, S. T., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21232 · Cited by 119
“to enhanced delivery of anticancer agents [5], there is the potential for synergism when agents such as AZD2171 are combined with chemotherapy drugs that target the tumor cell itself.”
Backgrounddi Tomaso, E., Capen, D. E., Haskell, A., Hart, J., Logie, J. J., Jain, R. K., McDonald, D. M., Jones, R. C., & Munn, L. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4552 · Cited by 132
Self-citationEvaluating Biomaterial- and Microfluidic-Based 3D Tumor Models
Carvalho, M. R., Lima, D., Reis, R. L., Correlo, V. M., & Oliveira, J. M. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.09.009 · Cited by 122
“Organ-on chip models that integrate vasculature have the potential to transform in vitro approaches for the study of cancer [39,40], offering the possibilities of spatially resolved delivery and extraction of solvents and solutes to control the biochemistry of the microenvironment of the tumor, growth of appropriate e…”
Wang, A.-T., Liang, D.-S., Liu, Y., & Qi, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.077 · Cited by 115
The role of tumor-associated macrophages in tumor vascularization
Guo, C., Buranych, A., Sarkar, D., Fisher, P. B., & Wang, X.-Y. (2013) · Vascular Cell · doi:10.1186/2045-824x-5-20 · Cited by 114
“In addition to facilitating tumor angiogenesis, TAMs also induce abnormal tumor vessels in the hypoxic TME [32], thereby rendering tumors more resistant to cytotoxic therapies [150-152].”
The role of semaphorins and their receptors in vascular development and cancer
Gu, C., & Giraudo, E. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.02.003 · Cited by 127
“The restoration of this equilibrium in tumors induces a more functional and normalized vasculature [67].”
BackgroundTissue vascularization through 3D printing: Will technology bring us flow?
Paulsen, S. J., & Miller, J. S. (2015) · Developmental Dynamics · doi:10.1002/dvdy.24254 · Cited by 119
The Role of the Transcription Factor KLF2 in Vascular Development and Disease
Novodvorský, P., & Chico, T. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386930-2.00007-0 · Cited by 114
Bevacizumab in ovarian cancer: A critical review of phase III studies
Rossi, L., Verrico, M., Zaccarelli, E., Papa, A., Colonna, M., Strudel, M., Vici, P., Bianco, V., & Tomao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13310 · Cited by 112
“Already it has showed that increased angiogenesis, evaluated with increased tumor microvessel density (MVD), plays an unfavourable therapeutic effect since it is related with a reduced delivery and availability of chemotherapeutic drugs; this mechanism impaired clinical outcome in many tumors, including OC [15-18].”
BackgroundApelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Uribesalgo, I., Hoffmann, D., Zhang, Y., Kavirayani, A., Lazovic, J., Berta, J., Novatchkova, M., Pai, T., Wimmer, R. A., László, V., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809266 · Cited by 114
“Preventing cancer hypoxia may therefore provide a mechanistic rationale for combination therapy with chemotherapeutics and radiation therapy, other anti-angiogenic treatments, perhaps even immune therapy (Mauceri et al, 1998; Jain, 2005).”
BackgroundOvercoming Drug Resistance and Treating Advanced Prostate Cancer
Semenas, J., Allegrucci, C., Boorjian, S. A., Mongan, N. P., & Persson, J. L. (2012) · Current Drug Targets · doi:10.2174/138945012802429615 · Cited by 125
“Consequently, oxygen supply and drug delivery to the tumor cells may be improved [138].”
BackgroundQuantification of Microvascular Tortuosity during Tumor Evolution Using Acoustic Angiography
Shelton, S. E., Lee, Y. Z., Lee, M., Chérin, E., Foster, F. S., Aylward, S., & Dayton, P. A. (2015) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2015.02.012 · Cited by 131
“The angiogenic factors produced by tumors (such as vascular endothelial growth factor, or VEGF) often cause increased vessel diameter, vascular density, permeability, as well as alterations in vessel structure (Jain 2005; Jain 2014).”
BackgroundModeling Melanoma In Vitro and In Vivo
Beaumont, K. A., Mohana‐Kumaran, N., & Haass, N. K. (2013) · Healthcare · doi:10.3390/healthcare2010027 · Cited by 129
“However, there is emerging evidence supporting the hypothesis that anti-angiogenic agents can also transiently ‘normalize’ the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery [43].”
BackgroundExperience With Bevacizumab in the Management of Epithelial Ovarian Cancer
Burger, R. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1509 · Cited by 113
Zhang, Y., Ji, W., Lian, H., Chen, Y., Ding, X., Sun, Y., Hu, S., Yang, H., Huang, W. T., Zhang, Y., et al. (2018) · Theranostics · doi:10.7150/thno.21575 · Cited by 116
Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue
Munir, M. U. (2022) · Cancers · doi:10.3390/cancers14122904 · Cited by 121
“The drug delivery is improved by normalizing the vascular networks and restoring the blood supply, causing enhanced penetration and optimized distribution of drugs at the tumor site [87].”
BackgroundMicelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
Lemon, C. M., Karnas, E., Han, X., Bruns†, O. T., Kempa, T. J., Fukumura, D., Bawendi, M. G., Jain, R. K., Duda, D. G., & Nocera, D. G. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b04765 · Cited by 119
Self-citationAngiogenesis in normal and neoplastic ovaries
Ramakrishnan, S., Subramanian, I. V., Yokoyama, Y., & Geller, M. A. (2005) · Angiogenesis · doi:10.1007/s10456-005-9001-1 · Cited by 122
Höbel, S., Koburger, I., John, M., Czubayko, F., Hadwiger, P., Vornlocher, H., & Aigner, A. M. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1431 · Cited by 120
“With regard to optimal therapeutic regimens, however, it should also be taken into consideration that anti-angiogenic effects may impair the delivery of other anti-cancer drugs as a result of the reduction of tumor vasculature, or may, in contrast, transiently increase drug delivery as a result of the ‘normalization’…”
BackgroundYang, Y., Zhang, Y., Iwamoto, H., Hosaka, K., Seki, T., Andersson, P., Lim, S., Fischer, C., Nakamura, M., Abe, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12680 · Cited by 112
Han, M. Y., Huang-Fu, M.-Y., Guo, W.-W., Guo, N., Chen, J., Liu, H.-N., Xie, Z., Lin, M., Wei, Q., & Gao, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10098 · Cited by 115
Hepatocellular carcinoma treatment: hurdles, advances and prospects
Kumari, R., V, Sahu, M. K., Tripathy, A., Uthansingh, K., & Behera, M. K. (2018) · Hepatic Oncology · doi:10.2217/hep-2018-0002 · Cited by 118
Chen, Z., Niu, M., Chen, G., Wu, Q., Tan, L., Fu, C., Ren, X., Zhong, H., Xu, K., & Meng, X. (2018) · ACS Nano · doi:10.1021/acsnano.8b07749 · Cited by 112
The role of N6-methyladenosine mRNA in the tumor microenvironment
Li, M., Zha, X., & Wang, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188522 · Cited by 123
Stromal Estrogen Receptor-α Promotes Tumor Growth by Normalizing an Increased Angiogenesis
Péqueux, C., Raymond-Letron, I., Blacher, S., Boudou, F., Adlanmerini, M., Fouque, M.-J., Rochaix, P., Noël, A., Foidart, J.-M., Krust, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3768 · Cited by 112
Wu, M., Frieboes, H. B., Chaplain, M. A. J., McDougall, S. R., Cristini, V., & Lowengrub, J. S. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.04.012 · Cited by 111
“Normalization of the tumor vasculature (Jain, 2005; Jain et al., 2007), e.g., decreasing the vascular hydraulic conductivity, has been suggested in tumor treatment in order to improve drug delivery into tumors.”
Zhao, B., Zhao, Y., Huang, Y., Luo, L.-M., Song, P., Wang, X., Chen, S., Yu, K., Zhang, X., & Zhang, Q. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.078 · Cited by 116
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.